Article Text

SP0057 Biologics in Lupus: Wihch and for Whom?
  1. R. F. Van Vollenhoven1
  1. 1Medicine, The Karolinska Institute, Stockholm, Sweden


Biologics in lupus: which and for whom?

With the regulatory approval of belimumab it may be said that the treatment of SLE has (finally!) entered the biologic age. In addition to this approved agent several other biologics have been used off-label, most notably rituximab. Two large randomized clinical trials of belimumab achieved their primary endpoints, whereas two trials each with rituximab and abatacept were nominally negative. However, in some of these trials trends were observed that suggest efficacy may nonetheless be present in certain subsets of patients. Several other biologics are currently in phase II or III clinical trials. So clinicians face important questions in the management of their patients: which biologics to consider, and for whom.

In this lecture, I will present some of the evidence that may help clinicians decide on these issues and use clinical cases to illustrate the certainties and uncertainties of biologics in SLE.

Disclosure of Interest R. Van Vollenhoven Grant/research support from: AbbVie, BMS, GSK, MSD, Pfizer, Roche, UCB, Consultant for: AbbVie, BMS, GSK, Lilly, MSD, Pfizer, Roche, UCB

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.